

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: WALLACH=24

Ī

Conf. No. 9660 In re Application of: Art Unit: 1642 David WALLACH Appln. No.: 09/445,223 Examiner: M. Davis Washington, D.C. Filed: December 6, 1999 February 28, 2002 For: MODULATORS OF INTRACELLULAR INFLAMMATION)

AMENDMENT

RECEIVED

Honorable Commissioner for Patents

MAR 0 6 2002

Washington, D.C. 20231

CELL DEATH, AND ...

TECH CENTER 1600/2900

Sir:

In response to the Office Action of November 28, 2001, petition for a three-month extension of time and payment thereof being attached hereto, please amend as follows:

IN THE CLAIMS

Please rewrite claims 44, 40-42, 11, 22-24, 29, 30, 36 and 37 in amended form as follows:

44 (Amended). \ A DNA sequence encoding a polypeptide which potentiates cell death, said polypeptide consisting of:

- a sequence comprising SEQ ID NO:1;
- a sequence comprising an analog of (a) having no more than ten changes in the amino acid sequence of (a), each said change being a substitution, deletion or insertion

BEST AVAILABLE COPY







AND TRADEMARK OFFICE

THE COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

THE COMMISSIONER OF PATENTS AND TRADEMARKS

In Re Application of: David WALLACH et al

Application No.: 90/445,223 Filed: December 6, 1999

Washington, D.C. 20231

For: MODULATOR'S OF INTRACELLULAR INFLAMMATION, CELL DEATH, AND

Art Unit: 1642

Examiner: M. Davis

Washington, D.C. Atty.'s Docket: WAL

Date: February 28, 2002

MAR 0 6 2002

TECH CENTER 1600/2900

OR

OR

Sir:

Transmitted herewith is a [X] Amendment [] Substitute Specification

in the above-identified application.

Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27. []

No additional fee is required. 1 1

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2) (Col. 3)				
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS			
TOTAL	* 35	MINUS	** 39	0			
INDEP.	* 5	MINUS	*** 3	0			
EIDST DDECENTATION OF MULTIDLE DED. CLAIM							

SMALL ENTITY				
RATE	ADDITIONAL FEE			
x 9	\$			
x 42	\$			
+ 140	\$			
IAL FEE TOTAL	\$			
	x 9 x 42 + 140			

	OTHER THAN SWALL ENTITY						
		RATE	ADDITIONAL FEE				
ļ	х	18	\$				
1	x	84	\$				
	+	280	\$				
		TOTAL	\$				

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

	Small Entity			Other Than Small Entity					
	Response Filed Within			Response Filed Within					
	[]	First	-	\$ 55.00	[]	First	-	\$	110.00
	[]	Second	-	\$ 200.00	[]	Second	-	\$	400.00
	[]	Third	-	\$ 460.00	[XX]	Third	-	\$	920.00
		Fourth	-	\$ 720.00	[]	Fourth	-	\$	1440.00
	Month A	After Time F	Perio	d Set	Month After Time Period Set				
	[] L	ess fees (\$) already paid for month(s) extension of time or	·			•	
[]	Please c	harge my l	Оерс	sit Account No. 02-4035 in the amount of \$	·				
[XX]	Credit C	ard Payme	nt Fo	orm, PTO-2038, is attached, authorizing payment in the	amount c	f \$ <u>920.00</u>			
[]	A check	in the amo	unt c	of \$ is attached (check no.).					
[XX]				ereby authorized and requested to charge any additional Account No. 02-4035. This authorization and request is					

920.00 CP

nection with this application or credit any ssociated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees

under 37 CFR §1.18.

03/C4/2002 JBRLINRN 00000119 09445223

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

(202) 737-3528 Facsimite: Telephone: (202) 628-5197

01 50:117

REST AVAILABLE COPY,

Roger L. Browdy Registration No. 25,618